IP Library Patent Application 16689740
Patent Application
App. No. 16/689,740

System and Method to Modulate Phrenic Nerve to Prevent Sleep Apnea

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/689,740
Abstract

An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic never through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.

Claims (18)

1 . A method of prolonging breath in a patient having a diaphragm innervated by a phrenic nerve and a vein near the phrenic nerve, the method comprising:

implanting a stimulation electrode in a vein of a patient proximate the phrenic nerve;

measuring respiration of the patient to find the inspiration phase of a breath; and

stimulating the phrenic nerve via the stimulation electrode after the beginning of the inspiration phase, said stimulation magnitude being sufficient to still the diaphragm resulting in a substantial amount of air trapped in at least one lung.

2 . The method of claim 1 further characterized by said stimulation beginning at a time after peak of the inspiration phase.

3 . The method of claim 1 further characterized by said stimulation duration being sufficient to delay expiration.

4 . The method of claim 1 further comprising: repeating measuring and stimulation steps for selected breaths.

5 . A method of prolonging breath in a patient having a diaphragm innervated by a phrenic nerve and a vein near the phrenic nerve, the method comprising:

implanting a stimulation electrode in a vein of a patient proximate the phrenic nerve;

measuring respiration of the patient to find the inspiration phase of a breath; and

stimulating the phrenic nerve via the stimulation electrode after the beginning of the inspiration phase, said stimulation duration exceeding a natural expiration phase of breath.

6 . The method of claim 5 further characterized by said stimulation beginning at a time after peak of the inspiration phase.

7 . The method of claim 5 further characterized by said stimulation duration being sufficient to prevent apnea.

8 . The method of claim 5 further comprising: repeating measuring and stimulation steps for selected breaths.

9 . A method of reducing breathing rate in a patient having a diaphragm innervated by a phrenic nerve and a vein near the phrenic nerve, the method comprising:

implanting a stimulation electrode in a vein of a patient proximate the phrenic nerve;

measuring respiration of the patient to find the inspiration phase of a breath; and

stimulating the phrenic nerve via the stimulation electrode after the beginning of the inspiration phase, said stimulation magnitude being sufficient to still the diaphragm resulting in a substantial amount of air trapped in at least one lung, said stimulation duration being sufficient to reduce breathing rate of the patient.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 056267 FRAME: 0334. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 25, 2021
From: RESPICARDIA, INC.
To: ZOLL RESPICARDIA, INC.
Reel/Frame 056366/0506 →
CHANGE OF NAME Recorded May 17, 2021
From: RESPICARDIA, INC.
To: ZOLL RESPICARDIA, INC.
Reel/Frame 056267/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2021
From: GELFAND, MARK; LEVIN, HOWARD R., M.D.; HALPERT, ANDREW
To: RESPICARDIA, INC.
Reel/Frame 055314/0799 →